Tech Company Financing Transactions
Vaxart Funding Round
Private investors invested in a $20 million Series C funding round for Vaxart. This venture round was announced on 8/6/2013.
Transaction Overview
Company Name
Announced On
8/6/2013
Transaction Type
Venture Equity
Amount
$19,999,997
Round
Series C
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing. Not a solicitation.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
395 Oyster Point Blvd. 405
South San Francisco, CA 94080
USA
South San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
The combination of adenovirus vector, adjuvant and oral administration will unlock the potential of vector-based vaccination, with applications in Avian Influenza response, biodefense vaccines, and second-generation versions of existing vaccines. The company is currently testing an avian flu vaccine.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Wouter Latour
Chief Financial Officer
John Harland
Chief Medical Officer
David Taylor
Chief Scientific Officer
Sean Tucker
VP - Manufacturing
David Ingamells
VP - Regulatory Affairs
Uday Patel
Browse more venture capital transactions:
Prev: 8/6/2013: Freedom Meditech venture capital transaction
Next: 8/6/2013: SentinelOne venture capital transaction
Share this article
News on VC Transactions
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs